Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics that target signaling pathways of the transforming growth factor-beta (TGF-β) family. The company is headquartered in Lexington, Massachusetts and was founded in 2015. Keros Therapeutics is developing product candidates for hematological, pulmonary, and neuromuscular disorders, including programs aimed at conditions with high unmet medical need. The company is publicly traded on Nasdaq under the ticker KROS. In 2023, Keros Therapeutics reported approximately $3.2 million in revenue. The company had about 180 employees in 2023.
Verified Email Pattern
{f}{last}@kerostx.com
a****@kerostx.com
a****@kerostx.com
Find a verified email at Keros Therapeutics
Look up any prospect by name, or by name and company, across 110M contacts.
Employees Directory
Showing 10 of 10 employees with verified contact records
| Name | Location | Verified Email |
|---|---|---|
|
Allie McGinty
Associate at Keros Therapeutics
|
|
a****@kerostx.com
|
|
Annita Tanini
Professional at Keros Therapeutics
|
|
a****@kerostx.com
|
|
Bart Giddings
He/Him
|
|
b****@kerostx.com
|
|
Bill Aschenbach
Chief Executive Officer
|
|
b****@kerostx.com
|
|
Carina Gonzalez
Research Scientist
|
|
c****@kerostx.com
|
|
Jasbir Seehra
Senior Scientist
|
|
j****@kerostx.com
|
|
Miranda Ross
Clinical Development Manager
|
|
m****@kerostx.com
|
|
Robin Wagner
Professional at Keros Therapeutics
|
|
r****@kerostx.com
|
|
Sara Campbell
Professional at Keros Therapeutics
|
|
s****@kerostx.com
|
|
Stefan Lanker
Research Scientist
|
|
s****@kerostx.com
|
Protected by reCAPTCHA. Google Privacy Policy and Terms of Service apply.